One in three young adults turns to AI for substance use

by rss feed | Oct 26, 2026 | News Feeds

More than 32% of participants in a Rutgers study reported using ChatGPT and similar chatbots for substance-use information. Read Original...

Geriatric chronic kidney disease patients benefit from SGLT2 inhibition

by rss feed | Oct 26, 2026 | News Feeds

New research uncovers the potential benefits and risks of sodium-glucose cotransporter 2 (SGLT2) inhibitors for adults aged 80 years or older with chronic kidney disease (CKD). The findings will be presented at ASN Kidney Week 2026 October 22–25. Read Original...

Airborne ESKAPE bacteria pose severe risks to immunocompromised patients

by rss feed | Oct 26, 2026 | News Feeds

At a clinic in South Africa, researchers have identified airborne ESKAPE bacteria which survive most antibiotic medicines. The clinic is in a densely populated inner-city area. Read Original...

Next generation KRAS inhibitor divarasib significantly extends lung cancer survival

by rss feed | Oct 26, 2026 | News Feeds

​Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The...

Phase 3 EMT2 trial demonstrates survival benefit for high-dose EPA

by rss feed | Oct 26, 2026 | News Feeds

Patients assigned to receive high-dose eicosapentaenoic acid (EPA), an omega-3 fatty acid, before and after surgery for colorectal cancer liver metastases had longer overall survival than those assigned to receive placebo, according to results of the phase 3 EMT2...